Insider Selling: Zepp Health (NYSE:ZEPP) CFO Sells 9,836 Shares

Zepp Health Corporation Sponsored ADR (NYSE:ZEPP) CFO Cheng Deng sold 9,836 shares of Zepp Health stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $4.61, for a total value of $45,343.96. Following the completion of the sale, the chief financial officer owned 114,539 shares of the company’s stock, valued at approximately $528,024.79. The trade was a 7.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zepp Health Price Performance

Zepp Health stock opened at $4.53 on Monday. The stock has a market capitalization of $66.43 million, a price-to-earnings ratio of -1.80 and a beta of 1.78. Zepp Health Corporation Sponsored ADR has a 52-week low of $2.50 and a 52-week high of $61.85. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.67 and a current ratio of 0.88. The stock’s 50 day moving average price is $9.78 and its two-hundred day moving average price is $17.13.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. FIL Ltd purchased a new position in Zepp Health during the 4th quarter valued at about $16,858,000. Millennium Management LLC grew its stake in Zepp Health by 49.1% during the fourth quarter. Millennium Management LLC now owns 366,826 shares of the company’s stock valued at $9,882,000 after acquiring an additional 120,750 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Zepp Health by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 295,967 shares of the company’s stock valued at $7,974,000 after acquiring an additional 44,619 shares in the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Zepp Health by 46.9% in the fourth quarter. Balyasny Asset Management L.P. now owns 202,775 shares of the company’s stock worth $5,463,000 after purchasing an additional 64,692 shares during the period. Finally, UBS Group AG boosted its stake in Zepp Health by 16,412.0% during the third quarter. UBS Group AG now owns 181,302 shares of the company’s stock valued at $8,300,000 after buying an additional 180,204 shares during the period. Institutional investors own 52.61% of the company’s stock.

Wall Street Analyst Weigh In

ZEPP has been the topic of a number of recent research reports. Fundamental Research set a $56.28 target price on Zepp Health and gave the stock a “buy” rating in a report on Wednesday, April 22nd. Wall Street Zen downgraded shares of Zepp Health from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.28.

About Zepp Health

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.